Researchers conduct a safety/feasibility study using psilocybin as an adjunct for quitting smoking.
Fifteen smokers (10 men) were examined in a 15-week open-label pilot study using psilocybin. After 6 months, 80% of the participants were still abstinent from smoking as determined by biomarker assessment and self-reporting. This far exceeds the cessation rate of <35% for other pharmacological and/or behavioral therapies.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.